Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma.

Abstract

BACKGROUND:

Hilar bile duct carcinoma has an 80% probability of local recurrence after curative resection, which might be reduced if neoadjuvant photodynamic therapy is feasible. CASE AND TREATMENT: After intravenous injection of sodium porfimer we treated an adenocarcinoma of the proximal common bile duct (T2 N0 M0, Bismuth type II) in a 72-year-old man with red laser light (applied from the lumen at a dose 250 Joules/cm2), and the adjacent right and left hepatic and common bile duct at a dose of 125 Joules/cm2. After 23 days the tumor was completely resected (adenocarcinoma pT2 pNO; G2).

RESULTS:

In the lumenal, 4-mm-thick layer the bile duct specimen exhibited complete tumor necrosis with pigmentation of photodegraded porfimer and no viable tumor cells, while in the outer layer of the wall (at 5-8-mm depth) viable cancer cell nests without degraded porfimer were seen. The bile duct tissue showed little damage. Eighteen months after surgery, neither tumor recurrence nor stricture formation was found at the pretreated bilioenteric anastomoses.

CONCLUSIONS:

a) Photodynamic therapy with sodium porfimer seems to be confined to the superficial 4-mm layer of bile duct cancer. b) Neoadjuvant photodynamic therapy is feasible for hilar bile duct carcinoma.

• Authors: F Berr, A Tannapfel, P Lamesch, S Pahernik, M Wiedmann, U Halm, A E Goetz, J Mössner, J Hauss
• Journal: Journal of hepatology (J Hepatol) Vol. 32 Issue 2 Pg. 352-7 (Feb 2000) ISSN: 0168-8278 [Print] Netherlands
• PMID: 10707878 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Dihematoporphyrin Ether

Topics

• Adenocarcinoma (drug therapy, surgery)
• Aged
• Antineoplastic Agents (therapeutic use)
• Bile Duct Neoplasms (drug therapy, surgery)
• Cholangiopancreatography, Endoscopic Retrograde
• Combined Modality Therapy
• Common Bile Duct
• Dihematoporphyrin Ether (therapeutic use)
• Feasibility Studies
• Humans
• Injections, Intravenous
• Male
• Neoadjuvant Therapy
• Photochemotherapy